The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Open accessAbstract
BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase 3 study, we assigned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kilogram of body weight) every 2 weeks or every 3 weeks or four doses of ipilimumab (at 3 mg per kilogram) every 3 weeks. Primary end points were progression-free and overall survival. RESULTS: The estimated 6-month progression-free-survival rates were 47.3% for pembrolizumab every 2 weeks, 46.4% for pembrolizumab every 3 weeks, and 26.5% for ipilimumab (hazard ratio for disease progression, 0.58; P<0.001 for both pembrolizumab regimens versus ipilimumab; 95% confidence intervals [CIs], 0.46 to 0.72 and 0.47 to 0.72, respectively). Estimated 12-month survival rates were 74.1%, 68.4%, and 58.2%, respectively (hazard ratio for death for pembrolizumab every 2 weeks, 0.63; 95% CI, 0.47 to 0.83; P=0.0005; hazard ratio for pembrolizumab every 3 weeks, 0.69; 95% CI, 0.52 to 0.90; P=0.0036). The response rate was improved with pembrolizumab administered every 2 weeks (33.7%) and every 3 weeks (32.9%), as compared with ipilimumab (11.9%) (P<0.001 for both comparisons). Responses were ongoing in 89.4%, 96.7%, and 87.9% of patients, respectively, after a median follow-up of 7.9 months. Efficacy was similar in the two pembrolizumab groups. Rates of treatment-related adverse events of grade 3 to 5 severity were lower in the pembrolizumab groups (13.3% and 10.1%) than in the ipilimumab group (19.9%). CONCLUSIONS: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp & Dohme; KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“however responses to these therapies are often heterogeneous and not durable (1–3).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [2]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials of ICPis excluded patients with pre-existing active autoimmune diseases because of concerns of a high susceptibility to severe irAEs [49,50].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with anti-PD-1 and anti-PD-1/CTLA-4 combination therapy emerging as most effective [3, 4].”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There were 16 responders (from here on, referred to as R) and 26 nonresponders (NR), yielding a response rate of 38%, which is in line with published clinical data of anti–PD-1 therapy in metastatic melanoma patients (5, 6).”
From The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients (2018) · cites this paper as [6]
In the citing paper
“Immune checkpoint blockade with monoclonal antibodies (mAbs) targeting programmed cell death protein 1 (PD-1) provides long-term clinical benefits to nearly 40% of patients with advanced melanoma (1–5).”
From Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients (2021) · cites this paper as [5]
In the citing paper
“Severe adverse reactions include severe diarrhea, colitis, increased alanine aminotransferase levels, inflammation pneumonitis, and interstitial nephritis (67, 73, 99).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [73]
In the citing paper
“In the subsequent phase III clinical trial, more than 30% of patients with advanced melanoma achieved an objective response following pembrolizumab monotherapy compared with 12% of patients treated with ipilimumab alone (58).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [58]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [2]
In the citing paper
“In order to limit the risk of severe immune-related adverse events (irAEs) or exacerbation of underlying autoimmune or inflammatory disease, patients with preexisting autoimmune disorders (ADs) or those receiving systemic immunosuppression for organ transplantation have been universally excluded from clinical trials.3,4”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [4]
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Research works printed but not linked: 2
- Ribas A, 2014, Pigment Cell Melanoma Res, 27, 1223
- Robert C, 2014, Ann Oncol, 25, LBA34
Cited by
Sorted by citations
Items 301–400 of 1,039
Hwang, S. J. E., Carlos, G., Wakade, D., Byth, K., Kong, B. Y., Chou, S., Carlino, M. S., Kefford, R. F., & Fernández‐Peñas, P. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.10.029 · Cited by 307
Self-citationYue, E. W., Sparks, R. B., Polam, P. K., Modi, D., Douty, B. D., Wayland, B. R., Glass, B. M., Takvorian, A. G., Glenn, J., Zhu, W., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00391 · Cited by 306
The immune system and cancer evasion strategies: therapeutic concepts
Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12470 · Cited by 304
Kostine, M., Finckh, A., Bingham, C. O., Visser, K., Leipe, J., Schulze‐Koops, H., Choy, E., Benesova, K., Radstake, T. R. D. J., Cope, A. P., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217139 · Cited by 307
Self-citationThe efficacy of anti‐PD‐1 agents in acral and mucosal melanoma
Shoushtari, A. N., Munhoz, R. R., Kuk, D., Ott, P. A., Johnson, D. B., Tsai, K. K., Rapisuwon, S., Eroglu, Z., Sullivan, R. J., Luke, J. J., et al. (2016) · Cancer · doi:10.1002/cncr.30259 · Cited by 303
Self-citationImmuno-Oncology: Emerging Targets and Combination Therapies
Marshall, H. T., & Djamgoz, M. B. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00315 · Cited by 303
A review of glioblastoma immunotherapy
Medikonda, R. T., Dunn, G. P., Rahman, M., Fecci, P. E., & Lim, M. K. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03448-1 · Cited by 307
A snapshot of the PD-1/PD-L1 pathway
Ghosh, C., Luong, G., & Sun, Y. (2021) · Journal of Cancer · doi:10.7150/jca.57334 · Cited by 303
NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion
Lv, H., Lv, G., Chen, C., Zong, Q., Jiang, G., Ye, D., Cui, X., He, Y., Xiang, W., Han, Q. Y., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.021 · Cited by 304
PD-1 and PD-L1 antibodies in cancer: current status and future directions
Balar, A. V., & Weber, J. S. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1954-6 · Cited by 300
Safety of combining radiotherapy with immune-checkpoint inhibition
Hwang, W. L., Pike, L., Royce, T. J., Mahal, B. A. V., & Loeffler, J. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0046-7 · Cited by 299
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01597 · Cited by 297
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01986 · Cited by 300
Abdel-Wahab, N., Safa, H., Abudayyeh, A., Johnson, D. H., Trinh, V. A., Zobniw, C. M., Lin, H., Wong, M. K., Abdelrahim, M., Gaber, A. O., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0585-1 · Cited by 294
Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017
Ugurel, S., Röhmel, J., Ascierto, P. A., Flaherty, K. T., Grob, J., Hauschild, A., Larkin, J., Long, G. V., Lorigan, P. C., McArthur, G. A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.028 · Cited by 294
Self-citationNext-generation sequencing to guide cancer therapy
Gagan, J., & Allen, E. M. V. (2015) · Genome Medicine · doi:10.1186/s13073-015-0203-x · Cited by 293
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
Paulson, K. G., Voillet, V., McAfee, M. S., Hunter, D. S., Wagener, F. D., Perdicchio, M., Valente, W. J., Koelle, S., Church, C. D., Vandeven, N. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06300-3 · Cited by 293
Wallis, C. J. D., Butaney, M., Satkunasivam, R., Freedland, S. J., Patel, S. P., Hamid, O., Pal, S. K., & Klaassen, Z. W. A. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5904 · Cited by 294
Self-citationCastillo, M. D., Romero, F. A. R., Argüello, E., Kyi, C., Postow, M. A., & Redelman‐Sidi, G. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw539 · Cited by 292
PD‐1 Blockade Cellular Vesicles for Cancer Immunotherapy
Zhang, X., Wang, C., Wang, J., Hu, Q., Langworthy, B., Ye, Y., Sun, W., Lin, J., Wang, T., Fine, J. P., et al. (2018) · Advanced Materials · doi:10.1002/adma.201707112 · Cited by 292
Sun, J., Zhang, D., Wu, S., Xu, M., Zhou, X., Lu, X., & Ji, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00212-5 · Cited by 292
Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
Wang, C., Ye, Y., Hu, Q., Bellotti, A., & Gu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201606036 · Cited by 291
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. Q. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 297
Long, G. V., Weber, J. S., Infante, J. R., Kim, K. B., DAUD, A. I., Gonzalez, R. C., Sosman, J. A., Hamid, O., Schuchter, L. M., Cebon, J. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.9345 · Cited by 290
Self-citationZinzani, P. L., Ribrag, V., Moskowitz, C. H., Michot, J., Kuruvilla, J. G., Balakumaran, A., Zhang, Y., Chlosta, S., Shipp, M. A., & Armand, P. A. (2017) · Blood · doi:10.1182/blood-2016-12-758383 · Cited by 290
Sznol, M., Postow, M. A., Davies, M. J., Pavlick, A. C., Plimack, E. R., Shaheen, M. F., Veloski, C., & Robert, C. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.002 · Cited by 290
Self-citationABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Cang, S., Iragavarapu, C., Savooji, J., Song, Y., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0224-3 · Cited by 289
Many ways to resistance: How melanoma cells evade targeted therapies
Kozar, I., Margue, C., Rothengatter, S., Haan, C., & Kreis, S. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.02.002 · Cited by 289
Immune system and melanoma biology: a balance between immunosurveillance and immune escape
Passarelli, A. M., Mannavola, F., Stucci, L. S., Tucci, M., & Silvestris, F. (2017) · Oncotarget · doi:10.18632/oncotarget.22190 · Cited by 287
Immunotherapy in melanoma: Recent advances and future directions
Franklin, C., Livingstone, E., Roesch, A., Schilling, B., & Schadendorf, D. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.07.145 · Cited by 286
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
Gu, L., Chen, M., Guo, D., Zhu, H., Zhang, W., Pan, J., Zhong, X., Li, X., Qian, H., & Wang, X. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182692 · Cited by 286
Nanomaterials for cancer immunotherapy
Song, W., Musetti, S., & Huang, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.017 · Cited by 285
Kluger, H. M., Chiang, V., Mahajan, A. K., Zito, C. R., Sznol, M., Tran, T. T. T., Weiss, S. A., Cohen, J. V., Yu, J. B., Hegde, U. P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00204 · Cited by 284
Immunotherapy of Melanoma: Facts and Hopes
Weiss, S. A., Wolchok, J. D., & Sznol, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1550 · Cited by 284
Influencing factors and strategies of enhancing nanoparticles into tumors in vivo
Zhang, M., Gao, S., Yang, D., Fang, Y., Lin, X., Jin, X., Liu, Y., Liu, X., Su, K., & Shi, K. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.033 · Cited by 281
Renfro, L. A., & Sargent, D. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw413 · Cited by 281
Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.04.002 · Cited by 280
The genomic landscape of breast cancer and its interaction with host immunity
Luen, S. J., Virassamy, B., Savas, P. S., Salgado, R., & Loi, S. (2016) · The Breast · doi:10.1016/j.breast.2016.07.015 · Cited by 279
Foppen, M. H. G., Rozeman, E. A., van Wilpe, S., Postma, C., Snæbjörnsson, P., van Thienen, J. V., van Leerdam, M. E., van den Heuvel, M. M., Blank, C. U., van Dieren, J. M., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000278 · Cited by 279
Self-citationTinganelli, W., & Durante, M. (2020) · Cancers · doi:10.3390/cancers12103022 · Cited by 279
Delivanis, D. A., Gustafson, M. P., Bornschlegl, S., Merten, M. M., Kottschade, L., Withers, S., Dietz, A. B., & Ryder, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00448 · Cited by 278
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy
Fan, Y., & Moon, J. J. (2015) · Vaccines · doi:10.3390/vaccines3030662 · Cited by 278
Evaluation of dosing strategy for pembrolizumab for oncology indications
Freshwater, T., Kondic, A. G., Ahamadi, M., Li, C. H., de Greef, R., de Alwis, D. P., & Stone, J. A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0242-5 · Cited by 277
Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer
Prendergast, G. C., Malachowski, W. P., Mondal, A., Scherle, P., & Muller, A. J. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.07.004 · Cited by 277
Larkin, J., Chmielowski, B., Lao, C. D., Hodi, F. S., Sharfman, W. H., Weber, J. S., Suijkerbuijk, K. P. M., Azevedo, S. J., Li, H., Reshef, D. S., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0487 · Cited by 276
Self-citationLehrer, E. J., Peterson, J., Brown, P. D., Sheehan, J. P., Quiñones‐Hinojosa, A., Zaorsky, N. G., & Trifiletti, D. M. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.08.025 · Cited by 273
Systemic Therapy for Melanoma: ASCO Guideline
Seth, R., Messersmith, H. J., Kaur, V., Kirkwood, J. M., Kudchadkar, R. R., McQuade, J. L., Provenzano, A. F., Swami, U., Weber, J. S., Alluri, K. C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00198 · Cited by 273
Self-citationDriving gene-engineered T cell immunotherapy of cancer
Johnson, L. A., & June, C. H. (2016) · Cell Research · doi:10.1038/cr.2016.154 · Cited by 271
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Brochez, L., Chevolet, I., & Krüse, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.011 · Cited by 271
Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B. A. G., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., Testori, A., Lorigan, P. C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx339 · Cited by 269
Self-citationDermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
Sibaud, V., Meyer, N., Lamant, L., Vigarios, É., Mazières, J., & Delord, J. P. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000290 · Cited by 269
Ock, C.-Y., Keam, B., Kim, S., Lee, J., Kim, M., Kim, T. M., Jeon, Y. K., Kim, D., Chung, D. H., & Heo, D. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2834 · Cited by 269
Patterns of Response and Progression to Immunotherapy
Borcoman, É., Nandikolla, A. G., Long, G. V., Goel, S., & Tourneau, C. L. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200643 · Cited by 267
Self-citationCheng, N., Watkins-Schulz, R., Junkins, R. D., David, C. N., Johnson, B. M., Montgomery, S. A., Peine, K. J., Darr, D. B., Yuan, H., McKinnon, K. P., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120638 · Cited by 267
Engineering nanoparticles to locally activate T cells in the tumor microenvironment
Wang, D., Wang, T., Yu, H., Feng, B., Zhou, L., Zhou, F., Hou, B., Zhang, H., Luo, M., & Li, Y. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau6584 · Cited by 265
Spain, L. A., Walls, G., Julve, M., O’Meara, K., Schmid, T., Kalaitzaki, E., Turajlic, S., Gore, M. E., Rees, J. H., & Larkin, J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw558 · Cited by 264
Self-citationRelating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients
Peters, B. A., Wilson, M., Moran, U., Pavlick, A., Izsak, A., Wechter, T., Weber, J. S., Osman, I., & Ahn, J. (2019) · Genome Medicine · doi:10.1186/s13073-019-0672-4 · Cited by 263
Circulating biomarkers in patients with glioblastoma
Bark, J. M., Kulasinghe, A., Chua, B., Day, B. W., & Punyadeera, C. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0603-6 · Cited by 262
Molecular Markers and Targets in Melanoma
Teixidó, C., Castillo, P., Martínez-Vila, C., Arance, A. M., & Alós, L. (2021) · Cells · doi:10.3390/cells10092320 · Cited by 262
Self-citationAn unexpected N-terminal loop in PD-1 dominates binding by nivolumab
Tan, S., Zhang, H., Chai, Y., Song, H., Tong, Z., Wang, Q., Qi, J., Wong, G., Zhu, X., Liu, W. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14369 · Cited by 263
Sucker, A., Zhao, F., Pieper, N., Heeke, C., Maltaner, R., Stadtler, N., Real, B., Bielefeld, N., Howe, S., Weide, B., et al. (2017) · Nature Communications · doi:10.1038/ncomms15440 · Cited by 260
Kumagai, S., Togashi, Y., Sakai, C., Kawazoe, A., Kawazu, M., Ueno, T., Sato, E., Kuwata, T., Kinoshita, T., Yamamoto, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.016 · Cited by 260
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Giacomo, A. M. D., Mortier, L., Rutkowski, P. L., Hassel, J. C., McNeil, C. M., Kalinka‐Warzocha, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00995 · Cited by 259
Self-citationNanomaterials in tumor immunotherapy: new strategies and challenges
Zhu, X., & Li, S. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01797-9 · Cited by 263
Systemic treatments for metastatic cutaneous melanoma
Pasquali, S., Hadjinicolaou, A. V., Chiarion‐Sileni, V., Rossi, C. R., & D, S. M. M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011123.pub2 · Cited by 258
The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations
Kridin, K., & Ludwig, R. J. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00220 · Cited by 258
Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
Cerezo, M., Guemiri, R., Druillennec, S., Girault, I., Malka-Mahieu, H., Shen, S., Allard, D., Martineau, S., Welsch, C., Agoussi, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0217-1 · Cited by 257
Self-citationRogado, J., Sánchez-Torres, J. M., Romero-Laorden, N., Ballesteros, A. I., Pacheco-Barcia, V., Ramos-Leví, A., Arranz, R., Lorenzo, A., Gullón, P., Donnay, O., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.014 · Cited by 255
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
González-Rodríguez, E., Rodríguez‐Abreu, D., & on behalf of the Spanish Group for Cancer Immuno-Biotherapy (GETICA) (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0509 · Cited by 254
Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
Ralli, M., Botticelli, A., Visconti, I. C., Angeletti, D., Fiore, M., Marchetti, P., Lambìase, A., VINCENTIIS, M. D., & Greco, A. (2020) · Journal of Immunology Research · doi:10.1155/2020/9235638 · Cited by 254
Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer
Clarke, J. D., Panwar, B., Madrigal, A., Singh, D. K., Gujar, R., Wood, O., Chee, S., Eschweiler, S., King, E. V., Awad, A. S., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190249 · Cited by 255
Khair, D. O., Bax, H. J., Mele, S., Crescioli, S., Pellizzari, G., Khiabany, A., Nakamura, M., Harris, R. J. C., French, E., Hoffmann, R. M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00453 · Cited by 252
Usmani, S. Z., Schjesvold, F., Oriol, A., Karlin, L., Cavo, M., Rifkin, R. M., Yimer, H. A., LeBlanc, R., Takezako, N., McCroskey, R. D., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30109-7 · Cited by 251
Zimmer, L., Livingstone, E., Hassel, J. C., Fluck, M., Eigentler, T., Loquai, C., Haferkamp, S., Gutzmer, R., Meier, F. E., Mohr, P., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30417-7 · Cited by 251
Systemic Therapy for Melanoma: ASCO Guideline Update
Seth, R., Agarwala, S. S., Messersmith, H. J., Alluri, K. C., Ascierto, P. A., Atkins, M. B., Bollin, K. B., Chacon, M. R., Davis, N. B., Faries, M. B., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01136 · Cited by 251
Self-citationTumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
Lee, N., Zakka, L. R., Mihm, M. C., & Schatton, T. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.006 · Cited by 250
Mechanisms of immune activation and regulation: lessons from melanoma
Kalaora, S., Nagler, A., Wargo, J. A., & Samuels, Y. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00442-9 · Cited by 252
Teng, F., Meng, X., Kong, L., & Yu, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.11.014 · Cited by 249
Radiation effects on antitumor immune responses: current perspectives and challenges
Walle, T., Monge, R. M., Cerwenka, A., Ajona, D., Melero, I., & Lecanda, F. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017742575 · Cited by 250
Long, G. V., Atkinson, V. G., Cebon, J. S., Jameson, M. B., Fitzharris, B. M., McNeil, C. M., Hill, A. G., Ribas, A., Atkins, M. B., Thompson, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30428-x · Cited by 248
Self-citationCutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Amaral, T. M. S., Ottaviano, M., Arance, A. M., Blank, C. U., Chiarion‐Sileni, V., Donia, M., Dummer, R., Garbe, C., Gershenwald, J. E., Gogas, H. J., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.11.006 · Cited by 248
Self-citationSchreibelt, G., Bol, K. F., Westdorp, H., Wimmers, F., Aarntzen, E. H. J. G., Boer, T. D., van de Rakt, M. W. M. M., Scharenborg, N. M., de Boer, A. J., Pots, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2205 · Cited by 247
Self-citationAlmozyan, S., Çolak, D., Mansour, F. A., Alaiya, A. A., Al‐Harazi, O., Qattan, A. T., Almohanna, F., Al-Alwan, M. M., & Ghebeh, H. (2017) · International Journal of Cancer · doi:10.1002/ijc.30834 · Cited by 247
Targeted therapies for renal cell carcinoma
Posadas, E. M., Limvorasak, S., & Figlin, R. A. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.82 · Cited by 246
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
de Filette, J., Jansen, Y., Schreuer, M., Everaert, H., Velkeniers, B., Neyns, B., & Bravenboer, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2300 · Cited by 244
Self-citationManagement of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents
Weber, J. S., Postow, M. A., Lao, C. D., & Schadendorf, D. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0055 · Cited by 244
Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568931 · Cited by 243
Hong, X., Roh, W., Sullivan, R. J., Wong, K. H. K., Wittner, B. S., Guo, H., Dubash, T. D., Sade-Feldman, M., Wesley, B., Horwitz, E. P., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1500 · Cited by 243
TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
Du, W., Yang, M., Turner, A., Xu, C., Ferris, R. L., Huang, J., Kane, L., & Lu, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030645 · Cited by 242
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
Moreira, A., Loquai, C., Pföhler, C., Kähler, K. C., Knauß, S., Heppt, M. V., Gutzmer, R., Dimitriou, F., Meier, F. E., Mitzel-Rink, H., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.033 · Cited by 242
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Sullivan, R. J., Hamid, O., Gonzalez, R. C., Infante, J. R., Patel, M. R., Hodi, F. S., Lewis, K. D., Tawbi, H. A., Hernandez, G., Wongchenko, M. J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0474-7 · Cited by 242
Self-citationEtzerodt, A., Tsalkitzi, K., Maniecki, M. B., Damsky, W., Delfini, M., Baudoin, E., Moulin, M., Bosenberg, M., Graversen, J. H., Auphan‐Anezin, N., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182124 · Cited by 242
YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
Kim, M. H., Kim, C. G., Kim, S.-K., Shin, S. J., Choe, E. A., Park, S.-H., Shin, E.-C., & Kim, J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0320 · Cited by 241
The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications
Spiotto, M. T., Fu, Y., & Weichselbaum, R. R. (2016) · Science Immunology · doi:10.1126/sciimmunol.aag1266 · Cited by 241
Santoni, M., Romagnoli, E., Saladino, T., Foghini, L., Guarino, S., Capponi, M., Giannini, M., Cognigni, P. D., Ferrara, G., & Battelli, N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.007 · Cited by 241
Weinmann, S. C., & Pisetsky, D. S. (2019) · Rheumatology · doi:10.1093/rheumatology/kez308 · Cited by 243
Tolcher, A. W., Sznol, M., Hu‐Lieskovan, S., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Gravio, D. D., Huang, B., Gambhire, D., Chen, Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1243 · Cited by 240
Chao, Y., Liang, C., Tao, H., Du, Y., Wu, D., Dong, Z., Jin, Q., Chen, G., Xu, J., Xiao, Z., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz4204 · Cited by 239
Hiniker, S. M., Reddy, S. A., Maecker, H. T., Subrahmanyam, P. B., Rosenberg‐Hasson, Y., Swetter, S. M., Saha, S., Shura, L., & Knox, S. J. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.07.005 · Cited by 238
The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy
Galle, P. R., Tovoli, F., Foerster, F., Wörns, M., Cucchetti, A., & Bolondi, L. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.007 · Cited by 238
Metadata
- Authors
- Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C. U., Hamid, O., Mateus, C., Shapira-Frommer, R., Kosh, M., Zhou, H., Ibrahim, N., Ebbinghaus, S., & Ribas, A.
- Affiliations
- Université Paris-Sud (FR)
- Sheba Medical Center (IL)
- Hospital Clínic de Barcelona (ES)
- Hôpital de la Timone (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- University of California, San Francisco (US)
- Royal Prince Alfred Hospital (AU)
- Hadassah Medical Center (IL)
- Royal Marsden Hospital (GB)
- University of Manchester (GB)
- Universitair Ziekenhuis Brussel (BE)
- The Netherlands Cancer Institute (NL)
- Angeles Clinic and Research Institute (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-06-25
- Volume
- 372
- Issue
- 26
- Pages
- 2521-2532
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152897456
- Semantic Scholar
- 0dac3ea80083f0a86598cb9af0a205554280551b
- Cited by
- 5,887
- References
- 26
- Citations by year
- 2026: 234 · 2025: 298 · 2024: 374 · 2023: 421 · 2022: 471 · 2021: 568 · 2020: 659 · 2019: 585 · 2018: 684 · 2017: 761 · 2016: 628 · 2015: 188
- FWCI
- 329.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Genentech
- Kite Pharma
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- ipilimumab, advanced melanoma, immune checkpoint inhibitors, anti-PD-1 therapy, CTLA-4 inhibition, progression-free survival, overall survival, dosing frequency, treatment-related adverse events, immune-related adverse events, response rate
- MeSH terms
- Ipilimumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Survival Analysis, Young Adult, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
